Hannover Rück SE

  • WKN: 840221
  • ISIN: DE0008402215
  • Land: Deutschland

Nachricht vom 09.10.2014 | 11:00

Hannover Re wins award for innovation

Hannover Rück SE / Key word(s): Miscellaneous

09.10.2014 / 11:00

Hannover Re wins award for innovation

Hannover, 9 October 2014: At this year's Insurance Conference Munich (inscom) Hannover Re was the recipient of the "I3 Award" in the category of Design Innovation for the "Energie Einspar Protect" (EEP), an energy savings product developed jointly with b2b Protect GmbH.

The prize is awarded in recognition of business models, services and products designed by companies that have the potential to deliver fresh impetus to the insurance sector and further advance the industry's development.

The EEP policy enables providers of energy-saving measures to offer their customers a warranty for the efficiency of their solution. If the measure fails to deliver the promised savings, the customer receives a compensatory payment from the insurer. This product opens up new potential to generate premium while at the same time making an active contribution to climate protection.

"We see this award as affirmation of our continued efforts to develop new risk solutions going forward and thereby position ourselves as an innovative partner for our clients", Chief Executive Officer Ulrich Wallin stated.

For further information please contact:

Corporate Communications:
Karl Steinle (tel. +49 511 5604-1500,
e-mail: karl.steinle@hannover-re.com)

Media Relations:
Gabriele Handrick (tel. +49 511 5604-1502,
e-mail: gabriele.handrick@hannover-re.com)

Investor Relations:
Axel Bock (tel. +49 511 5604-1736,
e-mail: axel.bock@hannover-re.com)

Please visit: www.hannover-re.com
Hannover Re, with gross premium of EUR 14.0 billion, is the third-largest reinsurer in the world. It transacts all lines of property/casualty and life/health reinsurance and is present on all continents with around 2,400 staff. The rating agencies most relevant to the insurance industry have awarded Hannover Re very strong insurer financial strength ratings (Standard & Poor's AA- "Very Strong" and A.M. Best A+ "Superior").

Please note the disclaimer:

09.10.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

290704  09.10.2014

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021